

Drug discovery
5
papers
On emerging therapies
Overview
Cholestasis-lymphedema syndrome (CLS) is a rare autosomal recessive disorder caused by UNC45A variants, characterized by neonatal cholestasis (often intermittent) and chronic lower-limb lymphedema. Complications include fat malabsorption, vitamin deficiencies, pruritus, and progressive liver disease (25% develop cirrhosis). Management focuses on nutritional support, symptom control, and multidisciplinary care [1][6][11][16].
Burden
Chronic liver and lymphatic dysfunction lead to recurrent hospitalizations, growth delays, and skeletal abnormalities [4][6].
Severe lymphedema correlates with reduced mental health and physical function; 12% of Norwegian patients require liver transplantation [6][11].
High healthcare utilization due to lifelong multidisciplinary care needs [6][9].
Therapies
Cholestasis: Cholestyramine (pruritus), fat-soluble vitamin supplementation, ursodeoxycholic acid, and liver transplantation for cirrhosis [3][11][16].
Lymphedema: Compression garments, decongestive lymphatic therapy, and surgical interventions (e.g., lymphovenous anastomosis) in advanced stages [8][17].
Diet: Fat-restricted during cholestatic episodes to reduce malabsorption [13].